Acute aortic dissection (AAD), one of the fatal diseases observed at the department of vascular surgery, is associated with a great mortality rate at the early stage. Ceruloplasmin (CP) is the plasma protein that functions as a copper transporter. The current retrospective research was carried out to assess CP contents and to examine the possible part in diagnosing patients with AAD. In addition, propensity score matching (PSM) was also utilized for reducing the bias in case screening as well as the clinical confounders. Using PSM, this study included 85 pairs of AAD cases (Stanford A and B dissection) and matched controls, and their CP levels were also detected through enzyme-linked immunosorbent assay (ELISA). Additionally, the relative clinical data were extracted from participants included in this study. After PSM adjustment for clinical variables, including gender, age, body mass index (BMI), heart ratio (HR), smoking, hypertension, diabetes mellitus, coronary heart disease (CHD), and stroke, the serum CP contents among AAD cases were remarkably increased compared with those among the normal subjects. Besides, the CP contents showed independent association with the AAD risk. Typically, the CP level was significantly positively correlated with platelet (R = 0.329) or C-reactive protein (R = 0.340) level. Meanwhile, the area under the receiver operating characteristic (ROC) curve (AUC) was 0.929 when CP was used to diagnose AAD, and the best threshold value was 36.82mg/dL. Serum CP content significantly increased in cases with thrombosed false lumen (FL) relative to those in patent FL cases. Results of logistic regression analysis suggested that a greater CP content indicated an increased thrombosed FL risk (OR = 1.11; 95% CI: 1.01–1.23; P = 0.040). Findings in this study suggest that serum ceruloplasmin contents evidently increased among acute aortic dissection cases. CP shows close correlation with the inflammatory factors among AAD cases. Further, CP may serve as the candidate biomarker to diagnose AAD and to identify an increased risk of thrombosed false lumen.

急性主动脉夹层（AAD）是在血管外科部门观察到的致命疾病之一，与早期的高死亡率相关。铜蓝蛋白（CP）是充当铜转运蛋白的血浆蛋白。目前的回顾性研究旨在评估CP含量，并检查诊断AAD的可能部分。此外，倾向评分匹配（PSM）也可用于减少病例筛查以及临床混杂因素的偏倚。使用PSM，本研究包括85对AAD病例（斯坦福A和B夹层）和相匹配的对照，并且还通过酶联免疫吸附测定（ELISA）检测了它们的CP水平。此外，从本研究中包括的参与者中提取了相关的临床数据。在对PSM进行性别，年龄，体重指数（BMI），心率（HR），吸烟，高血压，糖尿病，冠心病（CHD）和中风等临床变量的调整后，AAD患者的血清CP含量为与正常人相比明显增加。此外，CP含量与AAD风险呈独立关联。通常，CP水平与血小板显着正相关（R  = 0.329）或C反应蛋白（R  = 0.340）水平。同时，使用CP诊断AAD时，接收器工作特性（ROC）曲线（AUC）下的面积为0.929，最佳阈值为36.82mg / dL。血栓性假内腔（FL）患者的血清CP含量相对于专利FL病例显着增加。Logistic回归分析的结果表明，较高的CP含量表明血栓形成的FL风险增加（OR = 1.11； 95％CI：1.01-1.23；P = 0.040）。这项研究的结果表明，在急性主动脉夹层病例中，血清铜蓝蛋白含量明显增加。CP与AAD病例中的炎症因子密切相关。此外，CP可以用作候选生物标志物以诊断AAD并鉴定血栓形成的假内腔的风险增加。